Stock BEAM BEAM THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
23.85 USD +3.34% Intraday chart for Beam Therapeutics Inc. +3.47% -12.38%
Jul. 01 Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 3000 Growth Index CI
Jul. 01 Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 3000E Growth Index CI

Summary

  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
BEAM THERAPEUTICS INC. Stock Beam Therapeutics Inc.
-12.38% 1.88B
C-
MODERNA, INC. Stock Moderna, Inc.
+17.09% 44.63B
B-
LONZA GROUP AG Stock Lonza Group AG
+42.10% 40.46B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-9.70% 38.07B
B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+33.28% 32.27B
B
CELLTRION, INC. Stock Celltrion, Inc.
-8.98% 27.3B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.37% 26.53B
B-
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.11% 14.06B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.33% 12.54B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.26% 11.28B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BEAM Stock
  4. Ratings Beam Therapeutics Inc.